標題: | Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial |
作者: | Abat, S. Abd Rahman, R. Abdul Cader, R. Abdul Hafidz, M. I. Abdul Wahab, M. Z. Abdullah, N. K. Abdul-Samad, T. Abe, M. Abraham, N. Acheampong, S. Achiri, P. YI-DER JIANG Cheng, HT FENG-JUNG YANG etc. Acosta, J. A. Adeleke, A. Adell, V. Adewuyi-Dalton, R. Adnan, N. Africano, A. Agharazii, M. Aguilar, F. Aguilera, A. Ahmad, M. Ahmad, M. K. Ahmad, N. A. Ahmad, N. H. Ahmad, N. I. Ahmad Miswan, N. Ahmad Rosdi, H. Ahmed, I. Ahmed, S. Aiello, J. Aitken, A. AitSadi, R. Aker, S. Akimoto, S. Akinfolarin, A. Akram, S. Alberici, F. Albert, C. Aldrich, L. Alegata, M. Alexander, L. Alfaress, S. Alhadj Ali, M. Ali, A. Alicic, R. Aliu, A. Almaraz, R. Almasarwah, R. Almeida, J. Aloisi, A. Al-Rabadi, L. Alscher, D. Alvarez, P. Al-Zeer, B. Amat, M. Ambrose, C. Ammar, H. An, Y. Andriaccio, L. Ansu, K. Apostolidi, A. Arai, N. Araki, H. Araki, S. Arbi, A. Arechiga, O. Armstrong, S. Arnold, T. Aronoff, S. Arriaga, W. Arroyo, J. Arteaga, D. Asahara, S. Asai, A. Asai, N. Asano, S. Asawa, M. Asmee, M. F. Aucella, F. Augustin, M. Avery, A. Awad, A. Awang, I. Y. Awazawa, M. Axler, A. Ayub, W. Azhari, Z. Baccaro, R. Badin, C. Bagwell, B. Bahlmann-Kroll, E. Bahtar, A. Z. Baigent, C. Bains, D. Bajaj, H. Baker, R. Baldini, E. Banas, B. Banerjee, D. Banno, S. |
公開日期: | 一月-2024 |
卷: | 12 |
期: | 1 |
來源出版物: | The lancet. Diabetes & endocrinology |
摘要: | The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/640731 |
ISSN: | 22138587 |
DOI: | 10.1016/S2213-8587(23)00322-4 |
顯示於: | 醫學院附設醫院 (臺大醫院)
|